

Japanese investors back a Cambridge Life Sciences firm, Storm Therapeutics

12 January 2018 | News

The financing will enable Storm, which is focused on developing small molecule therapies modulating RNA modifying enzymes to expand and accelerate its pipeline, pursue emerging therapeutic opportunities, and build a broader drug discovery platform encompassing new drug targets from additional academic collaborators and its scientific founders.



Storm Therapeutics, a Cambridge Life Sciences firm has attracted an additional £4m cash injection to its £12m Series A financing announced last year. The money comes from Taiho Ventures, the venture capital arm of Tokyo-based Taiho Pharmaceuticals.

The financing will enable Storm, which is focused on developing small molecule therapies modulating RNA modifying enzymes to expand and accelerate its pipeline, pursue emerging therapeutic opportunities, and build a broader drug discovery platform encompassing new drug targets from additional academic collaborators and its scientific founders.

Taiho joins existing backers Merck Ventures, Cambridge Innovation Capital, Pfizer Venture Investments and Touchstone Innovations Sakae Asanuma, president of Taiho Ventures, has taken a seat on the board at Babraham-based Storm.